Characterization of Human A2B Adenosine Receptors: Radioligand Binding, Western Blotting, and Coupling to Gqin Human Embryonic Kidney 293 Cells and HMC-1 Mast Cells

Abstract

Recombinant human A2B adenosine receptors (A2BARs) and receptors extended on the amino terminus with hexahistidine and the FLAG epitope, DYKDDDDK (H/F-A2B) were stably overexpressed (to >20,000 fmol/mg protein) in human embryonic kidney 293 cells (HEK-A2B). By Western blotting, the H/F-A2Breceptor runs as a 34.8-kDa glycoprotein. Pharmacological properties of A2BARs were characterized with125I-3-aminobenzyl-8-phenyl-(4-oxyacetic acid)-1-propylxanthine (KD, 36 nM). In competition binding assays, the affinity of agonists is reduced by substitution on either the N6- or the C-2 position of the adenine ring, whereas 5′-substitutions increase affinity, resulting in the potency order: 5′-N-ethylcarboxamidoadenosine (NECA) ≫N6-aminobenzyl-NECA ≈2-chloroadenosine > 2-[4-(2-carboxyethyl)phenethylamino]-NECA (CGS21680) >N6-aminobenzyladenosine. The A2BAR is potently blocked by the A2A-selective antagonist 4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo-[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol (ZM241385; KI, 32 nM for A2B, 1.4 nM for A2A) and the A1 selective antagonist 8-cyclopentyl-1,3-dipropylxanthine (KI, 50.5 nM for A2B; 2.5 nM for A1). TheKI values for the antiasthmatic xanthines, theophylline (7.8 μM) and enprofylline (6.4 μM), are below their therapeutic plasma concentrations (20 to 50 μM), and agree withKI determinations for inhibition of NECA-stimulated cAMP accumulation in HEK-A2B cells. NECA orN6-(2-iodo)benzyl-5′-N-methylcarboxamidodoadenosine (IB-MECA) stimulate inositol trisphosphates and calcium accumulation in HEK-A2B or HEK-A3 cells, respectively, but only the A3 response is prevented by pertussis toxin. In human HMC-1 mast cells, A2BAR activation stimulates calcium mobilization and cAMP accumulation. We conclude that HEK-A2B cells and HMC-1 mast cells possess A2BAR glycoproteins that are coupled to both Gq/11 and Gs.

Footnotes

  • Send reprint requests to: Dr. Joel Linden, Departments of Internal Medicine and Molecular Physiology, Box MR4 6012, Room MR4 6071, Health Sciences Center, University of Virginia, Charlottesville, Virginia. E-mail:jlinden{at}virginia.edu

  • This work was supported by National Institutes of Health Grant RO1-HK37942.

  • Abbreviations:
    AR
    adenosine receptor
    DPX
    1,3-diethyl-8-phenylxanthine
    CPX
    8-cyclopentyl-1,3-dipropylxanthine
    XAL
    8-(4-((2-aminoethyl)aminocarbonyl-methyloxy)phenyl)-1,3-dipropylxanthine
    ABOPX
    3-(3,4-aminobenzyl)-8-(4-oxyacetate)phenyl-1-propyl-xanthine
    H/F-A2B
    recombinant human A2B adenosine receptors extended on the amino terminus with hexahistidine and the FLAG epitope (DYKDDDDK)
    NECA
    5′-N-ethylcarboxamidoadenosine
    CPA
    N6-cyclopentyladenosine
    CGS21680
    2-[4-(2-carboxyethyl)phenethylamino]-5N-N-ethylcarboxamidoadenosine
    XAC
    8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine
    ABA
    N6-aminobenzyladenosine
    BW-A1433
    8-(4-carboxyethenylphenyl)-1,3-dipropylxanthine
    AB-NECA
    aminobenzyl-5′-N-ethylcarboxamidoadenosine
    DMEM
    Dulbecco’s modified Eagle’s medium
    APE
    2-[2-(4-amino-phenyl)ethylamino]adenosine
    TBS/T
    Tris-buffered saline/Tween 20
    CHO
    Chinese hamster ovary
    IP3
    inositol trisphosphate
    IB-MECA
    N6-(2-iodo)benzyl-5′-N-methylcarboxamidodoadenosine
    • Received March 5, 1999.
    • Accepted June 21, 1999.
« Previous | Next Article »Table of Contents